Skip to main content

Table 1 Characteristics of studies included in the pooled analyses

From: Response by sex to statin plus ezetimibe or statin monotherapy: A pooled analysis of 22,231 hyperlipidemic patients

Protocol Number
[citation]
Treatment Randomized to
Statin
Randomized to Statin+EZ Inclusion Criteria
   Men
(N = 5389)
Women
(N = 5142)
Men
(N = 6140)
Women
(N = 5607)
Min LDL-C Max LDL-C
005
[37]
PBO, EZ
EZ+S 10, 20, 40, 80
S 10, 20, 40, 80
172 177 169 184 145 mg/dL 250 mg/dL
011
[38]
PBO, EZ
S 10, 20, 40, 80
EZ+S 10, 20, 40, 80
110 153 126 148 145 mg/dL 250 mg/dL
021
[15]
S 20 + EZ
Doubling S to 40
61 49 62 42 101 mg/dL not specified
023
[25]
S 20,
EZ+S 10, 20, 40
158 95 292 165 130 mg/dL not specified
025
[39]
A 10
EZ + S 10, 20
131 131 279 247 not at LDL-C goal as defined by NCEP ATP III
030
[40]
A 10 + EZ
Doubling A to 20
171 145 159 146 130 mg/dL not specified
038
[11]
PBO, EZ
EZ/S 10, 20, 40, 80
S 10, 20, 40, 80
307 315 296 313 145 mg/dL 250 mg/dL
040
[18]
Ongoing statin + PBO
Ongoing statin + EZ
510 500 1073 947 not at LDL-C goal as defined by NCEP ATP III
051
[41]
EZ/S 10, 20, 40, 80
A 10, 20, 40, 80
498 453 496 455 not at LDL-C goal as defined by NCEP ATP III
058
[42]
EZ/S 10, 20, 40, 80
R 10, 20, 40
624 857 678 800 145 mg/dL 250 mg/dL
077
[43]
EZ/S 20, 40
A 10, 20, 40
361 374 221 273 100 mg/dL not specified
079
[12]
A 20 + EZ
Doubling to A 40
49 49 58 40 100 mg/dL 160 mg/dL
090
[16]
A 40 + EZ
Doubling to A 80
178 113 173 115 70 mg/dL 160 mg/dL
107
[20]
EZ/S 20, 40
A 10, 20, 40
379 307 266 191 70 mg/dL
100 mg/dL
not specified
112
[22]
A 10 + EZ
A 20/40
249 277 241 286 70 mg/dL
100 mg/dL
160 mg/dL
679
[44]
PBO, EZ
L 10, 20, 40
EZ+L 10, 20, 40
88 132 86 106 145 mg/dL 250 mg/dL
691
[17]
PBO, EZ
P 10, 20, 40
EZ+P 10, 20, 40
101 104 83 121 145 mg/dL 250 mg/dL
692
[45]
PBO, EZ
A 10, 20, 40, 80
EZ+A 10, 20, 40, 80
95 153 107 148 145 mg/dL 250 mg/dL
700
[46]
S 20 + EZ
Double S to 40
19 15 33 33 130 mg/dL not specified
801
[23]
S 10, 20 + PBO
S 10, 20 + EZ
158 52 145 63 101 mg/dL 160 mg/dL
802
[47]
S 10, 20 + PBO
S 10, 20 + EZ
124 57 124 57 101 mg/dL 160 mg/dL
803/804
[24]
A 10, 20 + PBO
A 10, 20 + EZ
157 73 153 67 101 mg/dL 160 mg/dL
806
[48]
EZ/S 20
Doubling to A 20
128 86 141 80 101 mg/dL 160 mg/dL
807
[49]
EZ/S 20, 40
Doubling to A 20
108 111 224 218 not specified not specified
809
[13]
EZ/S 20
R10
185 119 185 129 100 mg/dL 160 mg/dL
2173/2246
[14]
Ongoing statin + EZ
Ongoing statin+ PBO
221 169 222 157 not at LDL-C goal as defined by NCEP ATP III
3377
[21]
EZ+S 20
S 20
47 76 48 76 145 mg/dL 250 mg/dL
  1. A = atorvastatin; EZ = ezetimibe; L = lovastatin; LDL-C = low-density lipoprotein cholesterolemia; NCEP ATP III = National Cholesterol Education Program Adult Treatment Panel III; P = pravastatin = S = simvastatin.